How Japanese Researchers Can Succeed in Commercializing Scientific Discoveries with an International Approach No.1(12:40)
Speakers: Akira Myoui and Neil Rosenblatt
Dialogue Between Neil Rosenblatt and Professor Akira Myoui on the Regenerative and Gene Therapy Project Professor Myoui explained Osaka University’s RECET program, stating that it aims to commercialize research outcomes as CGT (cell and gene therapies). The project involves major institutions including Osaka University, Kyoto University, the University of Tokyo, and the National Cancer Center. He emphasized the importance of a global perspective, particularly in the fields of gene therapy and rare diseases. He noted that the Japanese market alone is too limited, and global expansion is essential. He also highlighted the importance of risk-taking through startups. Reflecting on his own career, Professor Myoui shared that he began as a clinical orthopedic surgeon, later moved into research and entrepreneurship, and now serves as the Director of the Future Medical Center, overseeing all aspects of its operation. He mentioned that his experience in the United States was a turning point, where he began molecular biology in earnest and built valuable international networks.
Chapters
Overview of the Regenerative and Gene Therapy Project(00:00:28)
Professor Myoui explained the project’s mission to support the commercialization and product development of CGT innovations, with participation from four leading institutions: Osaka University, Kyoto University, the University of Tokyo, and the National Cancer Center.
The Need for Global Expansion(00:01:44)
He emphasized that treating rare diseases requires a global outlook. He explained the limitations of the domestic market in Japan and the importance of embracing risk through startups.
Building an International Ecosystem(00:03:56)
Professor Myoui discussed startup ecosystems in Boston and California and stressed the need for Japan to develop its own equivalent.
Career Development and Sharing of Experience(00:06:01)
Drawing from his own journey, Professor Myoui spoke about the value of both deep specialization and broad experience, offering advice to young researchers.
Speakers: Akira Myoui and Neil Rosenblatt
Dialogue Between Neil Rosenblatt and Professor Akira Myoui on the Regenerative and Gene Therapy Project Professor Myoui explained Osaka University’s RECET program, stating that it aims to commercialize research outcomes as CGT (cell and gene therapies). The project involves major institutions including Osaka University, Kyoto University, the University of Tokyo, and the National Cancer Center. He emphasized the importance of a global perspective, particularly in the fields of gene therapy and rare diseases. He noted that the Japanese market alone is too limited, and global expansion is essential. He also highlighted the importance of risk-taking through startups. Reflecting on his own career, Professor Myoui shared that he began as a clinical orthopedic surgeon, later moved into research and entrepreneurship, and now serves as the Director of the Future Medical Center, overseeing all aspects of its operation. He mentioned that his experience in the United States was a turning point, where he began molecular biology in earnest and built valuable international networks.
Chapters
Overview of the Regenerative and Gene Therapy Project(00:00:28)
Professor Myoui explained the project’s mission to support the commercialization and product development of CGT innovations, with participation from four leading institutions: Osaka University, Kyoto University, the University of Tokyo, and the National Cancer Center.
The Need for Global Expansion(00:01:44)
He emphasized that treating rare diseases requires a global outlook. He explained the limitations of the domestic market in Japan and the importance of embracing risk through startups.
Building an International Ecosystem(00:03:56)
Professor Myoui discussed startup ecosystems in Boston and California and stressed the need for Japan to develop its own equivalent.
Career Development and Sharing of Experience(00:06:01)
Drawing from his own journey, Professor Myoui spoke about the value of both deep specialization and broad experience, offering advice to young researchers.
How Japanese Researchers Can Succeed in Commercializing Scientific Discoveries with an International Approach No.2(2:26)
Speakers: Akira Myoui and Neil Rosenblatt
Dr. Myoui Emphasizes the Value of International Research Environments Through His Experience in the U.S. Dr. Myoui spoke about his experience in the United States and emphasized the excellence of an environment where people from around the world gather to conduct research and study together. In the medical field, he explained that the Future Medical Center is operated through a model where physicians perform surgeries while also conducting research, with vendors participating as well. Dr. Myoui himself serves as the Director of the Center and leads its operations. He also introduced the RECET program at Osaka University, led by Dr. Mitsui. This project supports the development of commercialization strategies for relatively early-stage research, aiming at practical application. The importance of taking a global perspective in this development was strongly emphasized.
Chapters
Experience in the U.S. and International Research Environment(00:00:07)
Dr. Myoui reflected on his time in the U.S., describing a dynamic, borderless research environment where scholars from around the world challenge one another and grow together.
Role at the Future Medical Center(00:01:15)
Dr. Myoui’s leadership at the Future Medical Center was highlighted, where he directs integrated initiatives combining clinical practice with medical research.
Overview of Osaka University's RECET Program(00:02:00)
Under Dr. Mitsui’s leadership, the RECET program was explained as a support initiative for commercializing early-stage research. The discussion also stressed the significance of a global development approach.
Speakers: Akira Myoui and Neil Rosenblatt
Dr. Myoui Emphasizes the Value of International Research Environments Through His Experience in the U.S. Dr. Myoui spoke about his experience in the United States and emphasized the excellence of an environment where people from around the world gather to conduct research and study together. In the medical field, he explained that the Future Medical Center is operated through a model where physicians perform surgeries while also conducting research, with vendors participating as well. Dr. Myoui himself serves as the Director of the Center and leads its operations. He also introduced the RECET program at Osaka University, led by Dr. Mitsui. This project supports the development of commercialization strategies for relatively early-stage research, aiming at practical application. The importance of taking a global perspective in this development was strongly emphasized.
Chapters
Experience in the U.S. and International Research Environment(00:00:07)
Dr. Myoui reflected on his time in the U.S., describing a dynamic, borderless research environment where scholars from around the world challenge one another and grow together.
Role at the Future Medical Center(00:01:15)
Dr. Myoui’s leadership at the Future Medical Center was highlighted, where he directs integrated initiatives combining clinical practice with medical research.
Overview of Osaka University's RECET Program(00:02:00)
Under Dr. Mitsui’s leadership, the RECET program was explained as a support initiative for commercializing early-stage research. The discussion also stressed the significance of a global development approach.
"How to say it?!” - How Japanese Researchers Can Present to International Investors(10:25)
Speakers: Hyalker Amaral and Neil Rosenblatt
A discussion was held about the development of a presentation deck titled 'How to Say It'. This deck is designed to help Japanese researchers enhance their presentation skills for Western investors. Drawing on feedback from experts in regenerative medicine from Spain, it offers presentation methods tailored for researchers at three levels: specialized scientists, general scientists, and investors. The deck includes insights from interviews with 20 experts, analysis of successful case studies, and a methodology that leverages MBA experience. Additionally, a second deck concerning the commercialization process, titled 'What It Takes', is also in the works.
Chapters
The aims of the project and the context behind it.
Neil explained that the goal of this project is to assist Japanese researchers in making effective presentations to Western investors, especially when it comes to funding for commercialization. This initiative was inspired by feedback from Spanish experts, who noted that although Japanese researchers have strong technical skills, they tend to struggle with storytelling in their presentations.
The various levels of a presentation and their key components.
Neil discussed the importance of presentations from three perspectives: as a specialized scientist, a general scientist, and an investor. They developed comprehensive materials that address 20 to 25 key topics, attitudes toward presentations, impromptu speaking, and storytelling techniques.
Methodology and sources of the research
Neil provided an in-depth explanation of the research process, drawing on his experiences from a top MBA program renowned for its focus on marketing and presentation skills. This included analysis of 18 successful presentation materials from companies such as Moderna and 20 interviews with industry experts.
How to conduct a Q&A session
Neil discussed the challenges that Japanese researchers encounter during Q&A sessions, emphasizing the importance of understanding language barriers and the investors' perspectives. They compiled a list of 24 common questions that include explanations of investor intentions and suggested strategies for responding.
A business-oriented and patient-centered approach
Neil emphasized the significance of understanding the commercialization process and its effects on patients. They pointed out that good science is just the 'entry ticket,' and researchers must grasp all the processes required to bring a product to market.
Future direction and supplementary materials
Neil mentioned that they are currently working on the second deck titled 'What It Takes'. This deck emphasizes the essential steps for successfully commercializing drugs in international markets and provides insights into the various types of investors and their roles.
Speakers: Hyalker Amaral and Neil Rosenblatt
A discussion was held about the development of a presentation deck titled 'How to Say It'. This deck is designed to help Japanese researchers enhance their presentation skills for Western investors. Drawing on feedback from experts in regenerative medicine from Spain, it offers presentation methods tailored for researchers at three levels: specialized scientists, general scientists, and investors. The deck includes insights from interviews with 20 experts, analysis of successful case studies, and a methodology that leverages MBA experience. Additionally, a second deck concerning the commercialization process, titled 'What It Takes', is also in the works.
Chapters
The aims of the project and the context behind it.
Neil explained that the goal of this project is to assist Japanese researchers in making effective presentations to Western investors, especially when it comes to funding for commercialization. This initiative was inspired by feedback from Spanish experts, who noted that although Japanese researchers have strong technical skills, they tend to struggle with storytelling in their presentations.
The various levels of a presentation and their key components.
Neil discussed the importance of presentations from three perspectives: as a specialized scientist, a general scientist, and an investor. They developed comprehensive materials that address 20 to 25 key topics, attitudes toward presentations, impromptu speaking, and storytelling techniques.
Methodology and sources of the research
Neil provided an in-depth explanation of the research process, drawing on his experiences from a top MBA program renowned for its focus on marketing and presentation skills. This included analysis of 18 successful presentation materials from companies such as Moderna and 20 interviews with industry experts.
How to conduct a Q&A session
Neil discussed the challenges that Japanese researchers encounter during Q&A sessions, emphasizing the importance of understanding language barriers and the investors' perspectives. They compiled a list of 24 common questions that include explanations of investor intentions and suggested strategies for responding.
A business-oriented and patient-centered approach
Neil emphasized the significance of understanding the commercialization process and its effects on patients. They pointed out that good science is just the 'entry ticket,' and researchers must grasp all the processes required to bring a product to market.
Future direction and supplementary materials
Neil mentioned that they are currently working on the second deck titled 'What It Takes'. This deck emphasizes the essential steps for successfully commercializing drugs in international markets and provides insights into the various types of investors and their roles.
Related Azabu Insights Article:
「Japan's Start-up Ecosystem:Lagging Behind but Full of Opportunity」
「Building a Nihon Rashii Japanese Startup Ecosystem」
Boston Trip Participant:
The Benefit to Researchers of Experiencing the Boston Start-up Ecosystem(10:22)
Speakers: Yasutaka Okita and Neil Rosenblatt
After graduating from Kyushu University, Dr. Okita specializes as an immunologist focusing on collagen diseases and allergic conditions. He is currently involved in outpatient care, research, and practical support at the Future Medical Center. During a visit to Boston, he learned about the significance of incubators and experienced the contrasts between the startup cultures in Japan and Boston. Additionally, he discussed the Reset Project and the practical support system in Osaka.
Chapters
Overview of Dr. Okita's professional background
Doctor Okita graduated from Kyushu University in 2010 and is currently working as an immunologist specializing in autoimmune diseases and allergies. He has experience in basic research and is actively engaged in addressing challenges in clinical practice.
Overview of Current Main Activities
This describes the parallel execution of several activities, including outpatient care, research initiatives, and support for practical implementation at the Future Medical Center. It specifically mentions participation in the TPP support team for the Reset Project and the responsibility for website development.
Overview of the purpose and outcomes of the visit to Boston
The purpose of the visit to Boston was to understand the significance of research support for the Reset Project. I shared insights on the realities faced in practical support, examples of ventures initiated by researchers, and the collaborations with incubators and venture capital.
An unforgettable experience in Boston
I detailed my experiences at the Incubator Lab Central, emphasizing the importance of creating an environment conducive to commercialization and the cultural differences with Japan. I noted that even the smallest steps taken during the preparatory stage were impressive due to the culture's focus on swift commercialization.
Future outlook and thoughts on 'RECET'
Reflections on future prospects and the desire for a fresh start. I would like to express my desire to develop outcomes that benefit patients through the commercialization of research. I showed my determination to link at least one result to practical application through the Reset Project.
The Benefit to Researchers of Experiencing the Boston Start-up Ecosystem(10:22)
Speakers: Yasutaka Okita and Neil Rosenblatt
After graduating from Kyushu University, Dr. Okita specializes as an immunologist focusing on collagen diseases and allergic conditions. He is currently involved in outpatient care, research, and practical support at the Future Medical Center. During a visit to Boston, he learned about the significance of incubators and experienced the contrasts between the startup cultures in Japan and Boston. Additionally, he discussed the Reset Project and the practical support system in Osaka.
Chapters
Overview of Dr. Okita's professional background
Doctor Okita graduated from Kyushu University in 2010 and is currently working as an immunologist specializing in autoimmune diseases and allergies. He has experience in basic research and is actively engaged in addressing challenges in clinical practice.
Overview of Current Main Activities
This describes the parallel execution of several activities, including outpatient care, research initiatives, and support for practical implementation at the Future Medical Center. It specifically mentions participation in the TPP support team for the Reset Project and the responsibility for website development.
Overview of the purpose and outcomes of the visit to Boston
The purpose of the visit to Boston was to understand the significance of research support for the Reset Project. I shared insights on the realities faced in practical support, examples of ventures initiated by researchers, and the collaborations with incubators and venture capital.
An unforgettable experience in Boston
I detailed my experiences at the Incubator Lab Central, emphasizing the importance of creating an environment conducive to commercialization and the cultural differences with Japan. I noted that even the smallest steps taken during the preparatory stage were impressive due to the culture's focus on swift commercialization.
Future outlook and thoughts on 'RECET'
Reflections on future prospects and the desire for a fresh start. I would like to express my desire to develop outcomes that benefit patients through the commercialization of research. I showed my determination to link at least one result to practical application through the Reset Project.
Related Azabu Insights Article:
「Japan's Researchers：Great at Basic Research; Struggling to Tell their Story to Investors」
New Article Posted: “Telling Your Story”(2:21)
Speakers: Hyalker Amaral and Neil Rosenblatt
Japanese researchers excel in basic research but face challenges in international communication. Based on interviews with opinion leaders in Europe, resources have been created—including a presentation guide on "how to express oneself"—to improve their presentation skills, especially the ability to convey complex information concisely.
Chapters
Background of the Article on Japanese Researchers' Communication Challenges
Neil explained that the article was inspired by key opinion leader interviews conducted in Europe about a year ago, where experts in regenerative medicine praised Japanese researchers for their technical skills but noted challenges in their ability to effectively communicate their work at international meetings.
Strengths of Japanese Researchers
Neil highlighted that Japanese researchers are recognized for their sound technical skills, creativity, and detailed approach in regenerative medicine, as noted by a prominent European key opinion leader who had experience giving TED talks.
Communication Challenges
Neil discussed how Japanese researchers often struggle to simplify complex information and present it in a way that is engaging and accessible to international audiences, which has been a consistent observation among experts.
Development of Support Resources
Neil mentioned that the article led to the creation of a presentation guide called 'how to say it,' aimed at helping Japanese researchers improve their presentation skills in international settings.
Speakers: Hyalker Amaral and Neil Rosenblatt
Japanese researchers excel in basic research but face challenges in international communication. Based on interviews with opinion leaders in Europe, resources have been created—including a presentation guide on "how to express oneself"—to improve their presentation skills, especially the ability to convey complex information concisely.
Chapters
Background of the Article on Japanese Researchers' Communication Challenges
Neil explained that the article was inspired by key opinion leader interviews conducted in Europe about a year ago, where experts in regenerative medicine praised Japanese researchers for their technical skills but noted challenges in their ability to effectively communicate their work at international meetings.
Strengths of Japanese Researchers
Neil highlighted that Japanese researchers are recognized for their sound technical skills, creativity, and detailed approach in regenerative medicine, as noted by a prominent European key opinion leader who had experience giving TED talks.
Communication Challenges
Neil discussed how Japanese researchers often struggle to simplify complex information and present it in a way that is engaging and accessible to international audiences, which has been a consistent observation among experts.
Development of Support Resources
Neil mentioned that the article led to the creation of a presentation guide called 'how to say it,' aimed at helping Japanese researchers improve their presentation skills in international settings.
JP Morgan Conference and Outlook for Life Sciences -2025(17:30)
Speakers: Hyalker Amaral and Neil Rosenblatt
The discussion revolved around the outlook for 2025 at the JP Morgan Healthcare Conference. Neil highlighted its significance as the largest healthcare investment conference that has been running for 42 years. Hyalker reported positive developments for 2025, including J&J's $15 billion acquisition of Intracellular and GSK's $1 billion purchase of IDRX. Additionally, discussions were held regarding the impact of the new Trump administration on the healthcare sector, Julie Kim's appointment as Global President of Takeda, and the NIH's considerations regarding the indirect cost cap for researchers.
Chapters
An Overview and Significance of the JP Morgan Healthcare Conference
Neil explained that JP Morgan is one of the largest investment banks in the world and has hosted an important healthcare conference for 42 years. This event brings together CEOs and key players in the life sciences sector to discuss industry trends and transactions at the start of the year.
Analysis of Transaction Flows for 2025.
Hyalker reported that 2025 was a very significant year for transactions, emphasizing J&J's $15 billion acquisition of Intracellular and GSK's $1 billion acquisition of IDRX. Additionally, the discussion highlighted the importance of patent expirations in 2025, which are projected to be roughly double those in 2011.
The mood of the market and the sentiment within the industry.
During the meeting, the speakers talked about the overall positive atmosphere, even amid concerns regarding the Trump administration's impact on healthcare. They also addressed possible drug pricing policies and expressed worries about Robert F. Kennedy Jr. taking on the responsibilities of overseeing healthcare and human services.
New Trends in Life Sciences
This discussion highlighted two major trends: GLP-1 and regenerative medicine/gene therapy. Neil and Hyalker underscored the growing interest in CRISPR Cas9 technology, especially in the advancements of cell and gene therapy within oncology and rare disease sectors.
The effects of changes in NIH funding
Neil discussed the announcement that the NIH will restrict indirect costs to 15%, a substantial drop from Harvard's previous rate of 69%. He elaborated on the implications for research funding in Boston, noting that Boston accounts for 54% of all NIH funding, and explained how this could impact research opportunities in Japan.
Speakers: Hyalker Amaral and Neil Rosenblatt
The discussion revolved around the outlook for 2025 at the JP Morgan Healthcare Conference. Neil highlighted its significance as the largest healthcare investment conference that has been running for 42 years. Hyalker reported positive developments for 2025, including J&J's $15 billion acquisition of Intracellular and GSK's $1 billion purchase of IDRX. Additionally, discussions were held regarding the impact of the new Trump administration on the healthcare sector, Julie Kim's appointment as Global President of Takeda, and the NIH's considerations regarding the indirect cost cap for researchers.
Chapters
An Overview and Significance of the JP Morgan Healthcare Conference
Neil explained that JP Morgan is one of the largest investment banks in the world and has hosted an important healthcare conference for 42 years. This event brings together CEOs and key players in the life sciences sector to discuss industry trends and transactions at the start of the year.
Analysis of Transaction Flows for 2025.
Hyalker reported that 2025 was a very significant year for transactions, emphasizing J&J's $15 billion acquisition of Intracellular and GSK's $1 billion acquisition of IDRX. Additionally, the discussion highlighted the importance of patent expirations in 2025, which are projected to be roughly double those in 2011.
The mood of the market and the sentiment within the industry.
During the meeting, the speakers talked about the overall positive atmosphere, even amid concerns regarding the Trump administration's impact on healthcare. They also addressed possible drug pricing policies and expressed worries about Robert F. Kennedy Jr. taking on the responsibilities of overseeing healthcare and human services.
New Trends in Life Sciences
This discussion highlighted two major trends: GLP-1 and regenerative medicine/gene therapy. Neil and Hyalker underscored the growing interest in CRISPR Cas9 technology, especially in the advancements of cell and gene therapy within oncology and rare disease sectors.
The effects of changes in NIH funding
Neil discussed the announcement that the NIH will restrict indirect costs to 15%, a substantial drop from Harvard's previous rate of 69%. He elaborated on the implications for research funding in Boston, noting that Boston accounts for 54% of all NIH funding, and explained how this could impact research opportunities in Japan.
Amyotrophic Lateral Sclerosis (ALS) Research(5:48)
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil and Hyalker are discussing ALS research. Hyalker experienced the loss of his mentor to ALS 21 years ago, while Neil explains that a friend's family is currently in the late stages of the disease. Through the Ice Bucket Challenge in 2014, they raised over $100 million, which has significantly advanced research in cell and gene therapies. The discussion highlights the important work of Professor Okano from Keio University, as well as the significance of assistive technologies and treatments for oxidative stress. Overall, there is an optimistic outlook regarding research opportunities and potential funding in the United States.
Chapters
A personal connection to ALS and a first discussion about it
Neil and Hyalker began the meeting by sharing their personal connections to ALS. Hyalker recounted how he lost his mentor 21 years ago, while Neil mentioned the family of a friend who is currently in the terminal stages of the disease.
Awareness and funding for ALS in the United States
Hyalker explained that ALS is referred to as Lou Gehrig's disease in the United States and discussed the significant impact of the 2014 Ice Bucket Challenge, which raised over $100 million for ALS research.
Current trends in research and the opportunities they present
Hyalker addressed the challenges associated with diagnosing and treating ALS, particularly highlighting new research in assistive technologies as well as cellular and gene therapies. Neil underscored the work of Professor Okano at Keio University.
Research directions and opportunities for the future
The speakers discussed treatments for oxidative stress and the opportunities available in the field of ALS for Japanese researchers, particularly focusing on potential research areas like regenerative medicine and gene therapy.
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil and Hyalker are discussing ALS research. Hyalker experienced the loss of his mentor to ALS 21 years ago, while Neil explains that a friend's family is currently in the late stages of the disease. Through the Ice Bucket Challenge in 2014, they raised over $100 million, which has significantly advanced research in cell and gene therapies. The discussion highlights the important work of Professor Okano from Keio University, as well as the significance of assistive technologies and treatments for oxidative stress. Overall, there is an optimistic outlook regarding research opportunities and potential funding in the United States.
Chapters
A personal connection to ALS and a first discussion about it
Neil and Hyalker began the meeting by sharing their personal connections to ALS. Hyalker recounted how he lost his mentor 21 years ago, while Neil mentioned the family of a friend who is currently in the terminal stages of the disease.
Awareness and funding for ALS in the United States
Hyalker explained that ALS is referred to as Lou Gehrig's disease in the United States and discussed the significant impact of the 2014 Ice Bucket Challenge, which raised over $100 million for ALS research.
Current trends in research and the opportunities they present
Hyalker addressed the challenges associated with diagnosing and treating ALS, particularly highlighting new research in assistive technologies as well as cellular and gene therapies. Neil underscored the work of Professor Okano at Keio University.
Research directions and opportunities for the future
The speakers discussed treatments for oxidative stress and the opportunities available in the field of ALS for Japanese researchers, particularly focusing on potential research areas like regenerative medicine and gene therapy.
Parkinson’s Disease(7:52)
Speakers: Hyalker Amaral and Neil Rosenblatt
In an interview about Parkinson's disease research, Hyalker, who has 30 years of experience in life sciences, spoke with Neil. They discussed the gap between researchers and commercial stakeholders, the significance of Levodopa treatment in the 1970s, and the current state of treatments. The conversation also touched on the rising incidence of diseases in high-income countries, new opportunities in cell and gene therapy, assistive technologies, and wearable devices, as well as various research projects focused on ALS, degenerative disc disease, and Down syndrome.
Chapters
Overview and objectives of the research presentation on Parkinson's disease
Hyalker explained that this presentation is crafted to be helpful not just for researchers but also for other stakeholders, including AMED and Osaka University. The aim is to bridge the gap between scientists dedicated to research and their supporters, especially highlighting aspects related to patients and the viewpoints of caregivers.
The professional background of Hyalker
Hyalker provided an in-depth account of their 30-year career in life sciences, having transitioned from IT and finance into marketing. They shared their experiences working at companies like Abbott, Genzyme, Astellas, Biogen, and Talaris, as well as spending five and a half years working abroad, in addition to their experience at two Japanese companies.
My experience with CAR-T therapy
Hyalker discussed his role in the initial setup and filling of CAR-T therapy, detailing his collaboration with Dr. Rubin from the University of Pennsylvania, as well as with Kite and Novartis. He also highlighted that Dr. Ahmed and Dr. Jun are the key inventors of the CAR-T concept.
Insights on the treatment of Parkinson's disease
Hyalker discussed the historical significance of levodopa treatment, which has remained the gold standard for over 30 years, with limited advancements aside from deep brain stimulation. They particularly addressed the rising incidence of the disease in high-income countries and mentioned the potential of new treatment options, including cell and gene therapies, as well as wearable technology. Previous research projects
Hyalker mentioned that this is their fourth clinical area project, and they have previously conducted studies on ALS, degenerative disc disease, and Down syndrome.
Speakers: Hyalker Amaral and Neil Rosenblatt
In an interview about Parkinson's disease research, Hyalker, who has 30 years of experience in life sciences, spoke with Neil. They discussed the gap between researchers and commercial stakeholders, the significance of Levodopa treatment in the 1970s, and the current state of treatments. The conversation also touched on the rising incidence of diseases in high-income countries, new opportunities in cell and gene therapy, assistive technologies, and wearable devices, as well as various research projects focused on ALS, degenerative disc disease, and Down syndrome.
Chapters
Overview and objectives of the research presentation on Parkinson's disease
Hyalker explained that this presentation is crafted to be helpful not just for researchers but also for other stakeholders, including AMED and Osaka University. The aim is to bridge the gap between scientists dedicated to research and their supporters, especially highlighting aspects related to patients and the viewpoints of caregivers.
The professional background of Hyalker
Hyalker provided an in-depth account of their 30-year career in life sciences, having transitioned from IT and finance into marketing. They shared their experiences working at companies like Abbott, Genzyme, Astellas, Biogen, and Talaris, as well as spending five and a half years working abroad, in addition to their experience at two Japanese companies.
My experience with CAR-T therapy
Hyalker discussed his role in the initial setup and filling of CAR-T therapy, detailing his collaboration with Dr. Rubin from the University of Pennsylvania, as well as with Kite and Novartis. He also highlighted that Dr. Ahmed and Dr. Jun are the key inventors of the CAR-T concept.
Insights on the treatment of Parkinson's disease
Hyalker discussed the historical significance of levodopa treatment, which has remained the gold standard for over 30 years, with limited advancements aside from deep brain stimulation. They particularly addressed the rising incidence of the disease in high-income countries and mentioned the potential of new treatment options, including cell and gene therapies, as well as wearable technology. Previous research projects
Hyalker mentioned that this is their fourth clinical area project, and they have previously conducted studies on ALS, degenerative disc disease, and Down syndrome.
Degenerative Disc Disease(10:52)
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil Rosenblatt and Hyalker Discuss Degenerative Disc Disease (DDD) Neil Rosenblatt engaged in a discussion with Hyalker about Degenerative Disc Disease (DDD). Hyalker explained that DDD is a natural age-related process in which the spinal discs gradually deteriorate. He noted that these discs have limited blood flow and poor self-repair capacity. While symptoms typically begin to appear in people in their 40s or 50s, the condition often progresses earlier, with many individuals showing signs after age 40. He also shared his own experiences, including undergoing physical therapy. He went on to describe the range of current treatment options, which span from conservative approaches like physical therapy and pain management, to more invasive procedures such as cortisone injections and radiofrequency ablation, and even surgical options like spinal fusion or artificial disc replacement. Regarding future treatments, he introduced emerging fields such as regenerative medicine using stem cells, growth factors, and gene editing. He emphasized that many of these approaches have yet to receive FDA approval, highlighting the significant opportunities ahead. From a business perspective, he pointed out the importance of international collaboration in research, stating that working across borders can lead to more innovative solutions. Neil Rosenblatt added that understanding competitive research dynamics can help uncover new perspectives and accelerate the path to market.
Chapters
Overview of DDD and Its Impact
Hyalker provided a detailed explanation of degenerative disc disease, describing it not as a conventional illness but rather a natural part of aging. He emphasized its widespread impact, especially among people over 40, and shared his personal experience.
Current Treatments
Hyalker outlined the range of existing treatment options, from conservative therapies like physical therapy and pain control to more invasive procedures such as steroid injections, radiofrequency ablation, spinal fusion, and artificial disc replacement.
Future Treatments and Research Outlook
He discussed new regenerative therapies, including stem cell treatment, growth factors, and gene-editing technologies. Although FDA approvals remain limited, he emphasized the significant potential in fields such as tissue engineering and biomaterial development.
Business and Competitive Perspectives
Hyalker stressed the importance of international research collaboration. Meanwhile, Neil Rosenblatt spoke about the benefits of understanding competitive research landscapes and the potential for rethinking strategies based on market trends.
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil Rosenblatt and Hyalker Discuss Degenerative Disc Disease (DDD) Neil Rosenblatt engaged in a discussion with Hyalker about Degenerative Disc Disease (DDD). Hyalker explained that DDD is a natural age-related process in which the spinal discs gradually deteriorate. He noted that these discs have limited blood flow and poor self-repair capacity. While symptoms typically begin to appear in people in their 40s or 50s, the condition often progresses earlier, with many individuals showing signs after age 40. He also shared his own experiences, including undergoing physical therapy. He went on to describe the range of current treatment options, which span from conservative approaches like physical therapy and pain management, to more invasive procedures such as cortisone injections and radiofrequency ablation, and even surgical options like spinal fusion or artificial disc replacement. Regarding future treatments, he introduced emerging fields such as regenerative medicine using stem cells, growth factors, and gene editing. He emphasized that many of these approaches have yet to receive FDA approval, highlighting the significant opportunities ahead. From a business perspective, he pointed out the importance of international collaboration in research, stating that working across borders can lead to more innovative solutions. Neil Rosenblatt added that understanding competitive research dynamics can help uncover new perspectives and accelerate the path to market.
Chapters
Overview of DDD and Its Impact
Hyalker provided a detailed explanation of degenerative disc disease, describing it not as a conventional illness but rather a natural part of aging. He emphasized its widespread impact, especially among people over 40, and shared his personal experience.
Current Treatments
Hyalker outlined the range of existing treatment options, from conservative therapies like physical therapy and pain control to more invasive procedures such as steroid injections, radiofrequency ablation, spinal fusion, and artificial disc replacement.
Future Treatments and Research Outlook
He discussed new regenerative therapies, including stem cell treatment, growth factors, and gene-editing technologies. Although FDA approvals remain limited, he emphasized the significant potential in fields such as tissue engineering and biomaterial development.
Business and Competitive Perspectives
Hyalker stressed the importance of international research collaboration. Meanwhile, Neil Rosenblatt spoke about the benefits of understanding competitive research landscapes and the potential for rethinking strategies based on market trends.
Related Azabu Insights Article:
「If you want to understand Trump's Second Presidency, understand the“Art of the Deal”」
「Shrinking and Changing the US Government」
「Affects on Global Healthcare and Life Sciences - Explaining the US's cuts of USAID, NIH, FDA Funding and Dropping Out of WHO, CDC, and the Appointments of Robert Kennedy Jr.」
STAT 2025 Breakthrough East Summit:
State of Cell & Gene Therapy and Impact of Trump Administration on Life Sciences(14:02)
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil and Hyalker spoke about the STAT 2025 Breakthrough East Summit held in New York on March 20, comparing it to the JP Morgan event in January. Hyalker pointed out a significant shift in market sentiment between the two events. The JP Morgan conference took place just before President Trump’s inauguration, amid many uncertainties, while at the STAT Summit, more concrete concerns were raised about the impact of policy on healthcare and science. The approximately 40 participants included industry leaders, biotechnology experts, investors, doctors, and researchers. On scientific and technological progress, James Wilson, CEO of JAMA Therapeutics, and Dr. Kiran Musunuru from the University of Pennsylvania discussed the current state of CRISPR gene therapy, describing a shift from “irrational exuberance” to “irrational pessimism” in the field. They advocated for the importance of platform-based approaches over one-shot treatments aimed at dramatic effects. Bill Nye, known as "The Science Guy," took the stage and passionately emphasized the importance of vaccines, particularly in the context of eradicating polio. The summit also addressed concerns over the new administration’s healthcare policies, vaccine skepticism, and the U.S. withdrawal from the WHO. Hyalker concluded by stating that the current situation presents a significant opportunity for Japan to take the lead in global science, especially as the U.S. faces challenges in maintaining its scientific leadership.
Chapters
Comparing Key Life Science Events
Neil introduced the "STAT 2025 Breakthrough East Summit" hosted by STAT News, comparing it to the earlier JP Morgan event. The summit, held in New York City, brought together key figures in the life sciences field for a major event.
Shift in Industry Sentiment
Hyalker explained the transition from the uncertainty at JP Morgan to the clearer concerns expressed at the STAT Summit. He especially highlighted growing anxiety over changes in healthcare policy and scientific institutions.
Conference Structure and Participants
At the event, 40 speakers—including industry leaders, biotechnology experts, and members of the STAT team—participated in 19 sessions. These were not formal presentations but rather discussions moderated by hosts.
Discussion on CRISPR and Gene Therapy
James Wilson and Dr. Kiran Musunuru spoke about the current state of CRISPR gene therapy, promoting a platform-based approach and new funding mechanisms through public-private partnerships.
Concerns About Healthcare Policy
Speakers expressed serious concerns about current healthcare policies, skepticism toward vaccines, and international health cooperation. Bill Nye specifically emphasized the importance of vaccines.
State of Cell & Gene Therapy and Impact of Trump Administration on Life Sciences(14:02)
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil and Hyalker spoke about the STAT 2025 Breakthrough East Summit held in New York on March 20, comparing it to the JP Morgan event in January. Hyalker pointed out a significant shift in market sentiment between the two events. The JP Morgan conference took place just before President Trump’s inauguration, amid many uncertainties, while at the STAT Summit, more concrete concerns were raised about the impact of policy on healthcare and science. The approximately 40 participants included industry leaders, biotechnology experts, investors, doctors, and researchers. On scientific and technological progress, James Wilson, CEO of JAMA Therapeutics, and Dr. Kiran Musunuru from the University of Pennsylvania discussed the current state of CRISPR gene therapy, describing a shift from “irrational exuberance” to “irrational pessimism” in the field. They advocated for the importance of platform-based approaches over one-shot treatments aimed at dramatic effects. Bill Nye, known as "The Science Guy," took the stage and passionately emphasized the importance of vaccines, particularly in the context of eradicating polio. The summit also addressed concerns over the new administration’s healthcare policies, vaccine skepticism, and the U.S. withdrawal from the WHO. Hyalker concluded by stating that the current situation presents a significant opportunity for Japan to take the lead in global science, especially as the U.S. faces challenges in maintaining its scientific leadership.
Chapters
Comparing Key Life Science Events
Neil introduced the "STAT 2025 Breakthrough East Summit" hosted by STAT News, comparing it to the earlier JP Morgan event. The summit, held in New York City, brought together key figures in the life sciences field for a major event.
Shift in Industry Sentiment
Hyalker explained the transition from the uncertainty at JP Morgan to the clearer concerns expressed at the STAT Summit. He especially highlighted growing anxiety over changes in healthcare policy and scientific institutions.
Conference Structure and Participants
At the event, 40 speakers—including industry leaders, biotechnology experts, and members of the STAT team—participated in 19 sessions. These were not formal presentations but rather discussions moderated by hosts.
Discussion on CRISPR and Gene Therapy
James Wilson and Dr. Kiran Musunuru spoke about the current state of CRISPR gene therapy, promoting a platform-based approach and new funding mechanisms through public-private partnerships.
Concerns About Healthcare Policy
Speakers expressed serious concerns about current healthcare policies, skepticism toward vaccines, and international health cooperation. Bill Nye specifically emphasized the importance of vaccines.
Down Syndrome - Current Treatment and Future of Research(8:43)
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil and Hyalker Discuss Down Syndrome Research and Patient Care in Depth Neil and Hyalker had an in-depth discussion about Down syndrome research and patient care. Hyalker explained that Down syndrome is a condition involving the 21st chromosome, with 90% of cases involving the presence of three chromosomes instead of the usual two. As maternal age increases, the incidence rate also rises—statistics show that the risk is about 1 in 1,400 for mothers in their early 20s, but about 1 in 100 for mothers at age 40. Regarding patient experiences, Hyalker noted that although individuals with Down syndrome often appear happy, they face many challenges. The average life expectancy has increased from 10 years to 47 years over the past few decades, but comprehensive care still requires collaboration among multiple specialists due to various coexisting medical conditions. On the research front, he spoke about ongoing efforts to address both comorbid conditions and the underlying genetic causes. He mentioned research into regression in Down syndrome supported by the U.S. National Institutes of Health (NIH), as well as Alzheimer’s-related studies being conducted at the University of Arizona. He also highlighted the continued difficulty in developing effective research models.
Chapters
Overview of Down Syndrome Genetics and Incidence Rates
Hyalker explained that Down syndrome is caused by genetic abnormalities on chromosome 21 and discussed how its incidence increases with maternal age, citing recent research findings.
Patient Experiences and Life Expectancy
He discussed how social stigma affects treatment and noted that the life expectancy of people with Down syndrome has significantly increased from 10 to 47 years. He also pointed out the resulting difficulties in leading an independent life.
Medical Complications and Required Care
Hyalker provided detailed insight into common complications such as cognitive impairment, heart issues, hearing loss, vision problems, and early-onset dementia, stressing the need for a comprehensive care team.
Current Research Directions
He described current research efforts including NIH-funded studies on regression and Alzheimer’s research at the University of Arizona. He noted that building reliable research models remains a major challenge.
Speakers: Hyalker Amaral and Neil Rosenblatt
Neil and Hyalker Discuss Down Syndrome Research and Patient Care in Depth Neil and Hyalker had an in-depth discussion about Down syndrome research and patient care. Hyalker explained that Down syndrome is a condition involving the 21st chromosome, with 90% of cases involving the presence of three chromosomes instead of the usual two. As maternal age increases, the incidence rate also rises—statistics show that the risk is about 1 in 1,400 for mothers in their early 20s, but about 1 in 100 for mothers at age 40. Regarding patient experiences, Hyalker noted that although individuals with Down syndrome often appear happy, they face many challenges. The average life expectancy has increased from 10 years to 47 years over the past few decades, but comprehensive care still requires collaboration among multiple specialists due to various coexisting medical conditions. On the research front, he spoke about ongoing efforts to address both comorbid conditions and the underlying genetic causes. He mentioned research into regression in Down syndrome supported by the U.S. National Institutes of Health (NIH), as well as Alzheimer’s-related studies being conducted at the University of Arizona. He also highlighted the continued difficulty in developing effective research models.
Chapters
Overview of Down Syndrome Genetics and Incidence Rates
Hyalker explained that Down syndrome is caused by genetic abnormalities on chromosome 21 and discussed how its incidence increases with maternal age, citing recent research findings.
Patient Experiences and Life Expectancy
He discussed how social stigma affects treatment and noted that the life expectancy of people with Down syndrome has significantly increased from 10 to 47 years. He also pointed out the resulting difficulties in leading an independent life.
Medical Complications and Required Care
Hyalker provided detailed insight into common complications such as cognitive impairment, heart issues, hearing loss, vision problems, and early-onset dementia, stressing the need for a comprehensive care team.
Current Research Directions
He described current research efforts including NIH-funded studies on regression and Alzheimer’s research at the University of Arizona. He noted that building reliable research models remains a major challenge.